Clinical Trial Update: Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating aprepitant triple therapy to prevent chemotherapy-induced nausea and vomiting in nondrinking and young women receiving moderat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting
• Gastrointestinal Neoplasms

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting | Phase 3 | Status: COMPLETED